65 Mesothelioma Evolution following a Diagnosis of Benign Pleural Inflammation: A Systematic Review and Meta-Analysis
Pleural Mesothelioma (PM) may be presaged by benign pleural inflammation, typically labelled non-specific pleuritis (NSP). NSP is common and presents a clinical challenge given divergent rates of subsequent PM in previous studies. Greater clarity on cohorts at highest risk would inform clinical decision-making and ongoing precision PM prevention research. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Mark Neilly, Katie Ferguson, Joshua Roche, Matthew Tate, Kevin Blyth Tags: Mesothelioma Source Type: research
64 Variability in patient pathways and experiences of care in peritoneal mesothelioma
This study explored variability in the care pathway of people with PM. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Stephanie Ejegi-Memeh, Samantha Westbrook, Virginia Sherborne, Clare Warnock, Sophia Stanford, Lynne Squibb, Caroline Twist, Clare Gardiner Tags: Mesothelioma Source Type: research
63 Real-world outcomes of Nivlolumab-Ipilimumab combination therapy in unresectable malignant mesothelioma: Mount Vernon Cancer Centre Experience
We report real-world toxicity and outcomes from several hospitals within our Trust. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Tabitha Achim, Mujtaba Ehsan, Karen Henderson, Thalia Afxentiou, Vikash Dodhia, Wendy Ng, Ridwan Ahmed, Andreas Polychronis, Geirgios Antoniou, Ernese Xhafa-Hamati, Arshi Denton, Suzannah Mawdsley, Jeanette Dickson, Suprotim Basu, Suraiya Dubash Tags: Mesothelioma Source Type: research
62 Single-centre DGH experience of using immunotherapy for malignant mesothelioma
The treatment options for mesothelioma has expanded with the availability of immune checkpoint inhibitors; 2nd line Nivolumab in 2020 (interim COVID NICE guidance) and 1st line Ipilimumab& Nivolumab in 2022. This audit provides an overview of our initial experience with these drugs for mesothelioma. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Dan Patterson, Katie Ball Tags: Mesothelioma Source Type: research
61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma
RSO-021 is a first-in-class PRX3 inhibitor currently being investigated in a first-in-human phase 1/2 clinical trial called MITOPE, which is currently recruiting patients with malignant pleural effusion (MPE) arising from mesothelioma or other solid tumors (NCT05278975). Mesothelioma cells rely on buffering of mitochondrial oxidative stress through the expression and activity of mitochondrial PRX3, which is covalently inactivated by RSO-021. Inactivation of PRX3 by RSO-021 leads to increased oxidative stress and tumor cell death. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Brian Cunniff, Terri Messier, Victoria Gibson, David Seward, Essa Baitei, Peter Wells Jordan, Charlotte Poile, Joanna Dzialo, Aleksandra Bzura, Kudzayi Kutywayo, Apostolos Nakas, George Naumov, Dean Fennell Tags: Mesothelioma Source Type: research
60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience
We present our local experience of patients with MPM treated with Ipilimumab plus Nivolumab. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Aitzaz Qaisar, Mark White, Nicola Steele Tags: Mesothelioma Source Type: research
59 Immunotherapy Toxicities in Real-World Use of Nivolumab & Ipilimumab in Pleural Malignant Mesothelioma: Experience from Sussex Cancer Centre
Data from Checkmate 743 (CM743) study has established Nivolumab/ Ipilimumab (N/I) combination immunotherapy as the first line palliative treatment for Malignant Pleural Mesothelioma (MPM). Since July 2022, N/I have been available on the NHS via the Cancer Drug Fund. We retrospectively assessed the toxicity profile in MPM patients who received N/I as first line palliative treatment. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Cheung Lonn, Kam Zaki, Victoria Donovan, Kavita Kanlal Tags: Mesothelioma Source Type: research
58 Healthcare professionals ’ experience of nutritional management in mesothelioma: qualitative insights from the Help Meso Study
This study aimed to describe the perceptions and experiences of healthcare professionals in the nutritional management of patients with mesothelioma. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lorelle Dismore, Katherine Swainston, Christopher Hurst, Avinash Aujayeb, Leah Taylor Tags: Mesothelioma Source Type: research
57 Concurrent lung tumours and mesothelioma
The North-East of England has one of the highest incidence and case fatality rates for mesothelioma in the United Kingdom. Northumbria Healthcare NHS Foundation Trust has seen 317 cases from January 2009 till July 2023. Lung cancer appears simultaneously in approximately 1% of mesothelioma patients.1 We performed a review of the local database to ascertain our local incidence. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Mesothelioma Source Type: research
56 Simultaneous pneumothorax and mesothelioma
The North-East of England has one of the highest incidence and case fatality rates for mesothelioma in the United Kingdom. Northumbria Healthcare NHS Foundation Trust has seen 317 cases from January 2009 till July 2023. Mesothelioma presents very rarely as pneumothorax.1 We performed a review of the local database to ascertain our local incidence. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Mesothelioma Source Type: research
Reversible and monitorable nephrotoxicity in rats by the novel potent transcriptional enhanced associate domain (TEAD) inhibitor, K-975
In conclusion, this study revealed that in rats, oral K-975 treatment induced severe proteinuria by podocyte foot process effacement, which was reversible and monitorable by the urinary albumin index, suggesting important information for developing K-975 as an anticancer drug.PMID:38556354 | DOI:10.2131/jts.49.175 (Source: Journal of Toxicological Sciences)
Source: Journal of Toxicological Sciences - March 31, 2024 Category: Toxicology Authors: Hironori Otsuki Takeshi Uemori Yohei Inai Yui Suzuki Tetsuro Araki Ken-Ichiro Nan-Ya Kouichi Yoshinari Source Type: research
